Media Center Investor Relations Overview Investor News Press Releases Company Statements Media Kit Events Stock Information Stock Quote & Chart Analyst Coverage Ownership Profile Financials SEC Filings Annual Reports Governance Governance Documents Committee Composition Investor Resources Investor FAQs Settlement Information Contact Us Scientific Publications & Presentations Investor Email Alerts Investor contact760-603-2331Email Media contact760-603-4679Email Company Statements Aug 24, 2026 Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B Read More
Aug 24, 2026 Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B Read More
Aug 24, 2026 Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B Read More
